I received a very disheartening email from Eversull.
The marketing premise of Asepticsure is that it can reduce HAI's thereby saving hospitals significant dollars. In his Nov. 22 2010 message Ed said that after some additional testing to verify the safety to electronics they woudl commence Phase 2 hospital testing to verify that it does indeed reduce HAI's. Having heard no infomation regarding this testing I sent the following to Eversull:
1. In the November Chairmans message it was mentiobned that additional testing on electronics was taking place before more hospital testing would commence. Can you update me on the status of those tests. 2. When is hospital testing going to continue? 3. how long do they think this phase of the testing will take?
His response:
I don't believe that they are going to have to do additional testing. The beta test completed recently is all that is needed and they have completed the design of the Asepticsure and planning to start manufacturing and marketing with added staff based at the new headquarters facility . They seem focused on the medical journal peer review article and attending and presenting at medical conferences.
My follow-up question:
Do I understand correctly that they did more beta testing at a hospital and proved that they lowered the incidence of HAI's as per the Chairmans message dated 11/22/2010?
His response:
They are going to start manufacturing and selling product
So if I understand him correctly it sounds that they are planning to try to sell Asepticsure without ever proving that it works as claimed. I find it hard to believe that they will convince hospitals to spend $100,000 on an unproven machine.
Extremely disappointing! It also points to the fact that having Chairman's messages doesn't help if they aren't supplying important information. If they indeed changed their plan as far as hospital testing I would think that should have been deemed important to let us know.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.